Announcement
23.05.2012
NeuroSearch A/S (NEUR) advises that charges have been filed against the company for alleged share price manipulation as laid down in the Danish Securities Trading Act. The charges relate to an announcement issued on 3 February 2010 in which the then management of the company reported top-line results from the Phase III study with Huntexil® for the treatment of Huntington's disease (the MermaiHD study). The data were subsequently reassessed and on 28 April 2010, the company, on its own initiative, released a corrective announcement. On the present basis, NeuroSearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter.
Patrik Dahlen CEO
Contact person Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
About NeuroSearch NeuroSearch is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and ordopidine and seridopidine, which have both completed phase I development. Huntexil® is currently in Phase III development. The overall objective for NeuroSearch is to create a profitable, specialty pharma company building on the platform the company will achieve from a successful development and marketing of Huntexil®. The company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=393646
NeuroSearch A/S (NEUR) advises that charges have been filed against the company for alleged share price manipulation as laid down in the Danish Securities Trading Act. The charges relate to an announcement issued on 3 February 2010 in which the then management of the company reported top-line results from the Phase III study with Huntexil® for the treatment of Huntington's disease (the MermaiHD study). The data were subsequently reassessed and on 28 April 2010, the company, on its own initiative, released a corrective announcement. On the present basis, NeuroSearch is denying the charges and is collaborating fully with the authorities in order to resolve the matter.
Patrik Dahlen CEO
Contact person Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
About NeuroSearch NeuroSearch is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and ordopidine and seridopidine, which have both completed phase I development. Huntexil® is currently in Phase III development. The overall objective for NeuroSearch is to create a profitable, specialty pharma company building on the platform the company will achieve from a successful development and marketing of Huntexil®. The company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=393646
© 2012 GlobeNewswire
